Abivax SA Sponsored ADR (NASDAQ:ABVX) Receives $135.08 Average Target Price from Analysts

Shares of Abivax SA Sponsored ADR (NASDAQ:ABVX) have been given a consensus rating of “Moderate Buy” by the thirteen brokerages that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, eleven have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $135.0833.

Several brokerages have commented on ABVX. BTIG Research increased their price target on Abivax from $120.00 to $150.00 and gave the company a “buy” rating in a report on Thursday, January 8th. Truist Financial set a $140.00 target price on shares of Abivax in a research note on Monday, November 24th. Wolfe Research upgraded shares of Abivax to a “strong-buy” rating in a report on Thursday, November 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Abivax in a report on Wednesday, January 21st. Finally, Morgan Stanley lifted their price objective on Abivax from $101.00 to $145.00 and gave the stock an “overweight” rating in a research note on Friday, January 9th.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Kennedy Capital Management LLC increased its position in Abivax by 7.1% during the second quarter. Kennedy Capital Management LLC now owns 241,188 shares of the company’s stock worth $1,845,000 after acquiring an additional 15,997 shares during the period. Federated Hermes Inc. acquired a new stake in Abivax in the 3rd quarter worth $8,448,000. Privium Fund Management B.V. bought a new position in shares of Abivax during the 3rd quarter worth about $2,582,000. Voya Investment Management LLC acquired a new position in shares of Abivax during the third quarter valued at about $978,000. Finally, Simplify Asset Management Inc. bought a new stake in shares of Abivax in the third quarter valued at about $5,217,000. 47.91% of the stock is currently owned by institutional investors and hedge funds.

Abivax Price Performance

NASDAQ ABVX opened at $119.18 on Friday. Abivax has a fifty-two week low of $4.77 and a fifty-two week high of $148.83. The stock’s 50-day moving average is $122.15 and its two-hundred day moving average is $101.24. The firm has a market cap of $9.35 billion, a P/E ratio of -28.51 and a beta of 0.79. The company has a debt-to-equity ratio of 0.03, a current ratio of 7.86 and a quick ratio of 7.86.

Abivax (NASDAQ:ABVX) last issued its quarterly earnings data on Monday, December 15th. The company reported ($2.46) EPS for the quarter. The firm had revenue of ($4.92) million during the quarter. On average, analysts anticipate that Abivax will post -2.83 earnings per share for the current fiscal year.

About Abivax

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.